

Table S1

AMPK guide sequences

<u>Oligo name</u>	<u>Sequence</u>
PRKAB1-A-Fwd	caccGCAGCGCGGCGCGCTCACTGC
PRKAB1-A-Rev	aaacGCAGTGAGCGCGCCGCGCTGC
PRKAB1-B-Fwd	caccGTGGCCATAAGACGCCCGG
PRKAB1-B-Rev	aaacCCGGGGCGTCTTATGGCAC
PRKAA1-A-Fwd	caccGGCTGTCGCCATCTTCTCC
PRKAA1-A-Rev	aaacGGAGAAAGATGGCGACAGCC
PRKAA1-B-Fwd	caccGAAGATCGGCCACTACATT
PRKAA1-B-Rev	aaacGAATGTAGTGGCCGATCTTC
PRKAA2-A-Fwd	caccGTCAGCCATCTCGGCGCG
PRKAA2-A-Rev	aaacCGCGCGCCGAAGATGGCTGAC
PRKAA2-B-Fwd	caccGAAGATCGGACACTACGTGC
PRKAA2-B-Rev	aaacGCACGTAGTGTCCGATCTTC

Fwd: forward; Rev: reverse

Supplemental Figure 1




Fig. S1 FACS analysis of control and AMPK α -KO cells. Cells were treated with DMSO (control) (A, B) or Nocodazole (100 ng/mL for 20 h) (C, D) and cells were then stained by PI analyzed by flow cytometry. Numbers for each cell cycle phases are from three repeats.